Nonsteroidal anti-inflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts

References

• Loeser RF. Age-related changes in the musculoskeletal system and the development of osteoarthritis. Clin Geriatr Med. 2010;26:371–386.
   PubMed Web of Science ®Google Scholar
• Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105–118.
   PubMed Web of Science ®Google Scholar
• American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116:248–273.
   PubMed Web of Science ®Google Scholar
• American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112:810–833.
   PubMed Web of Science ®Google Scholar
• Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Pharm. 2013;19:S3–19.
   PubMed Web of Science ®Google Scholar
• Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147:478–491.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:465–474.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Clinical guideline 88. Low back pain: early management of persistent non-specific low back pain. 2009. [cited 2017 Mar 22]. Available from: http://www.nice.org.uk/guidance/cg88
   Google Scholar
• National Institute for Health and Care Excellence. Clinical guideline 177. Osteoarthritis: care and management in adults. 2014. cited 2017 Mar 22]. Available from: http://www.nice.org.uk/guidance/cg59
   Google Scholar
• Garcia Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3:98–101.
   PubMedGoogle Scholar
• Williams CM, Maher CG, Latimer J, et al. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet. 2014;384:1586–1596.
   PubMed Web of Science ®Google Scholar
• Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis. 2011;70:1534–1541.
   PubMed Web of Science ®Google Scholar
• Smyth EM, Grosser T, Wang M, et al. Prostanoids in health and disease. J Lipid Res. 2009;50:S423–8.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Patrono C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochim Biophys Acta. 2015;1851:422–432.
   PubMed Web of Science ®Google Scholar
• Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol. 2016;82:957–964.
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4–15.
   PubMed Web of Science ®Google Scholar
• Merck receives non approvable letter from FDA for arcoxia (etoricoxib). [cited 2017 Mar 22]. Available from: https://www.drugs.com/nda/arcoxia_070427.html
   Google Scholar
• Patrignani P, Tacconelli S, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. Ther Clin Risk Manag. 2008;4:983–997.
   PubMedGoogle Scholar
• Bhala N, Emberson J, Merhi A, et al. Coxib and traditional NSAID Trialists’ (CNT) collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–779.
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109:1468–1471.
   PubMed Web of Science ®Google Scholar
• Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res. 2006;98:593–595.
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Sciulli MG, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther. 2007;322:453–460.
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:413–421.
   PubMed Web of Science ®Google Scholar
• Taylor R Jr, Lemtouni S, Weiss K, et al. Pain management in the elderly: an FDA safe use initiative expert panel’s view on preventable harm associated with NSAID therapy. Curr Gerontol Geriatr Res. 2012;2012:196159.
   PubMedGoogle Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817.
   PubMed Web of Science ®Google Scholar
• Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295–1301.
   PubMed Web of Science ®Google Scholar
• Anzellotti P, Capone ML, Jeyam A, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum. 2011;63:850–859.
   PubMed Web of Science ®Google Scholar
• Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006;80:264–274.
   PubMed Web of Science ®Google Scholar
• Li X, Fries S, Li R, et al. Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA. 2014;111:16830–16835.
   PubMed Web of Science ®Google Scholar
• Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011;19:184–191.
   PubMed Web of Science ®Google Scholar
• Cryer B, Barnett MA, Wagner J, et al. Overuse and misperceptions of nonsteroidal anti-inflammatory drugs in the United States. Am J Med Sci. 2016;352:472–480.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375:2519–2529.
   PubMed Web of Science ®Google Scholar
• Adapt Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLOS Clin Trial. 2006;1:e33.
   PubMedGoogle Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA. Imprecision: limitations to interpretation of a large randomized clinical trial. Circulation. 2017;135:113–115.
   PubMed Web of Science ®Google Scholar
• Felson DT. Safety of nonsteroidal antiinflammatory drugs. N Engl J Med. 2016;375:2595–2596.
   PubMed Web of Science ®Google Scholar
• Gijón MA, Leslie CC. Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. J Leukoc Biol. 1999;65:330–336.
   PubMed Web of Science ®Google Scholar
• Balsinde J, Winstead MV, Dennis EA. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett. 2002;531:2–6.
   PubMed Web of Science ®Google Scholar
• Clark JD, Schievella AR, Nalefski EA, et al. phospholipase A2. J Lipid Mediat Cell Signal. 1995;12:83–117.
   PubMedGoogle Scholar
• Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387–437.
   PubMed Web of Science ®Google Scholar
• Rådmark O, Werz O, Steinhilber D, et al. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci. 2007;32:332–341.
   PubMed Web of Science ®Google Scholar
• Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41:163–181.
   PubMed Web of Science ®Google Scholar
• Marcus AJ. Transcellular metabolism of eicosanoids. Prog Hemost Thromb. 1986;8:127–142.
   PubMedGoogle Scholar
• Mohebati A, Milne GL, Zhou XK, et al. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res (Phila). 2013;6:646–655.
   PubMed Web of Science ®Google Scholar
• Fischer AR, Rosenberg MA, Lilly CMJ, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol. 1994;94:1046–1056.
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000.
   PubMed Web of Science ®Google Scholar
• Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007;50:470–479.
   PubMed Web of Science ®Google Scholar
• Kothapalli D, Stewart SA, Smyth EM, et al. Prostacyclin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol Pharmacol. 2003;64:249–258.
   PubMed Web of Science ®Google Scholar
• Fitzgerald DJ, Fitzgerald GA. Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res. 2013;112:174–194.
   PubMed Web of Science ®Google Scholar
• Di Francesco L, Totani L, Dovizio M, et al. Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Circ Res. 2009;104:506–513.
   PubMed Web of Science ®Google Scholar
• Topper JN, Cai J, Falb D, et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA. 1996;93:10417.
   PubMed Web of Science ®Google Scholar
• Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005;2:201–207.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Brash AR, Falardeau P, et al. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981;68:1272–1275.
   PubMed Web of Science ®Google Scholar
• Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137–1141.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983;67:1174–1177.
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735–741.
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272–277.
   PubMed Web of Science ®Google Scholar
• Dovizio M, Tacconelli S, Ricciotti E, et al. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. J Pharmacol Exp Ther. 2012;341:242–250.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116:1391–1399.
   PubMed Web of Science ®Google Scholar
• Yu Y, Ricciotti E, Scalia R, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4:132ra54.
   PubMed Web of Science ®Google Scholar
• Seta F, Chung AD, Turner PV, et al. Renal and cardiovascular characterization of COX-2 knockdown mice. Am J Physiol Regul Integr Comp Physiol. 2009;296:R1751–60.
   PubMed Web of Science ®Google Scholar
• Garcìa Rodrìguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52:1628–1636.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705–1712.
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pinca E, et al. Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17:317–327.
   PubMed Web of Science ®Google Scholar
• Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180–186.
   PubMed Web of Science ®Google Scholar
• Dovizio M, Bruno A, Tacconelli S, et al. Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res. 2013;191:39–65.
   PubMedGoogle Scholar
• Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82:85–94.
   PubMed Web of Science ®Google Scholar
• Needleman P, Moncada S, Bunting S, et al. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature. 1976;261:558–560.
   PubMed Web of Science ®Google Scholar
• Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–2494.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366–1372.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Tacconelli S, Piazuelo E, et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost. 2014;12:1320–1330.
   PubMed Web of Science ®Google Scholar
• Patrono C, García Rodríguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383.
   PubMed Web of Science ®Google Scholar
• Minuz P, Fumagalli L, Gaino S, et al. Rapid stimulation of tyrosine phosphorylation signals downstream of Gprotein- coupled receptors for thromboxane A2 in human platelets. Biochem J. 2006;400:127–134.
   PubMed Web of Science ®Google Scholar
• Catella F, Healy D, Lawson JA, et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA. 1986;83:5861–5865.
   PubMed Web of Science ®Google Scholar
• Sciulli MG, Renda G, Capone ML, et al. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther. 2006;80:115–125.
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev. 2007;59:207–224.
   PubMed Web of Science ®Google Scholar
• Kudo I, Murakami M. Prostaglandin E synthase: a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol. 2005;38:633–638.
   PubMedGoogle Scholar
• Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997;388:678–682.
   PubMed Web of Science ®Google Scholar
• Keogh JP, Allen A, Garner A. Relationship between gastric mucus synthesis, secretion and surface gel erosion measured in amphibian stomach in vitro. Clin Exp Pharmacol Physiol. 1997;24:844–849.
   PubMed Web of Science ®Google Scholar
• Kauffman GL Jr, Reeve JJ Jr, Grossman MI. Gastric bicarbonate secretion: effect of topical and intravenous 16,16-dimethyl prostaglandin E2. Am J Physiol. 1980;239:G44–8.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Araki H, Mizoguchi H, et al. Prostaglandin E inhibits indomethacin-induced gastric lesions through EP-1 receptors. Digestion. 2001;63:92–101.
   PubMed Web of Science ®Google Scholar
• Yokotani K, Okuma Y, Osumi Y. Inhibition of vagally mediated gastric acid secretion by activation of central prostanoid EP3 receptors in urethane-anaesthetized rats. Br J Pharmacol. 1996;117:653–656.
   PubMed Web of Science ®Google Scholar
• Morris G, Fallone C, Pringle G, et al. Gastric cytoprotection is secondary to increased mucosal fluid secretion: a study of six cytoprotective agents in the rat. J Clin Gastroenterol. 1998;27:S53–S63.
   PubMed Web of Science ®Google Scholar
• Gryglewski RJ, Szczeklik A, Wandzilak M. The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol. 1987;36:4209–4213.
   PubMed Web of Science ®Google Scholar
• Pihan G, Majzoubi D, Haudenschild C, et al. Early microcirculatory stasis in acute gastric mucosal injury in the rat and prevention by 16, 16-dimethyl prostaglandin E 2 or sodium thiosulfate. Gastroenterology. 1986;91:1415–1426.
   PubMed Web of Science ®Google Scholar
• Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504–2510.
   PubMed Web of Science ®Google Scholar
• Harris RC. Cyclooxygenase-2 and the kidney: functional and pathophysiological. J Hypertens. 2002;20:S3–S9.
   PubMed Web of Science ®Google Scholar
• Schlondorff D, Ardaillou R. Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney Int. 1986;29:108–119.
   PubMed Web of Science ®Google Scholar
• Yu Y, Stubbe J, Ibrahim S, et al. Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice. Circ Res. 2010;106:337–345.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Katoh T, Eiro M, et al. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. Circ J. 2005;69:124–126.
   PubMed Web of Science ®Google Scholar
• Kennedy CR, Zhang Y, Brandon S, et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med. 1999;5:217–220.
   PubMed Web of Science ®Google Scholar
• Narumiya S1, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193–1226.
   PubMed Web of Science ®Google Scholar
• Romero JC, Bentley MD, Vanhoutte PM, et al. Intrarenal mechanisms that regulate sodium excretion in relationship to changes in blood pressure. Mayo Clin Proc. 1989;64:1406–1424.
   PubMed Web of Science ®Google Scholar
• Tilley SL, Audoly LP, Hicks EH, et al. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J Clin Invest. 1999;103:1539–1545.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296:1619–1632.
   PubMed Web of Science ®Google Scholar
• Conlin P, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan. Hypertension. 2000;36:461–465.
   PubMed Web of Science ®Google Scholar
• Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477–484.
   PubMed Web of Science ®Google Scholar
• Wang D1, Patel VV, Ricciotti E, et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci USA. 2009;106:7548–7552.
   PubMed Web of Science ®Google Scholar
• Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108:7–13.
   PubMed Web of Science ®Google Scholar
• Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. XII th ed. Chapter 34 Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York City:McGraw-Hill Education/Medical. 2011.
   Google Scholar
• Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother. 2003;4:265–284.
   PubMed Web of Science ®Google Scholar
• Park JM, Lin YS, Calamia JC, et al. Transiently altered acetaminophen metabolism after liver transplantation. Clin Pharmacol Ther. 2003;73:545–553.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005;33:1567–1575.
   PubMed Web of Science ®Google Scholar
• Punzi L, Doherty M, Zhang W, et al. Italian consensus on EULAR recommendations 2005 for the management of hip osteoarthritis. Reumatismo. 2006;58:301–309.
   PubMedGoogle Scholar
• Agrawal NG, Rose MJ, Matthews CZ, et al. Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol. 2003;43:1136–1148.
   PubMed Web of Science ®Google Scholar
• Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145–182.
   PubMed Web of Science ®Google Scholar
• Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids. 2005;73:141–162.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term arthritis safety study. Jama. 2000;284:1247–1255.
   PubMed Web of Science ®Google Scholar
• Huntjens DR, Danhof M, la Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology. 2005;44:846–859.
   PubMed Web of Science ®Google Scholar
• Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014;129:907–916.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Tacconelli S, Bruno A, et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 2011;4:605–621.
   PubMedGoogle Scholar
• Sciulli MG, Seta F, Tacconelli S, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. Br J Pharmacol. 2003;138:634–641.
   PubMed Web of Science ®Google Scholar
• Franssen MJ, Tan Y, van de Putte LB, et al. Pharmacokinetics of naproxen at two dosage regimens in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1986;24:139–142.
   PubMed Web of Science ®Google Scholar
• Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38:225–242.
   PubMed Web of Science ®Google Scholar
• Brune K, Renner B, Hinz B. Using pharmacokinetic principles to optimize pain therapy. Nat Rev Rheumatol. 2010;6:589–598.
   PubMed Web of Science ®Google Scholar
• Brooks P, Kubler P. Etoricoxib for arthritis and pain management. Ther Clin Risk Manag. 2006;2:45–57.
   PubMedGoogle Scholar
• Brune K, Furst DE. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology. 2007;46:911–919.
   PubMed Web of Science ®Google Scholar
• Blower PR. The unique pharmacological profile of nabumetone. J Rheumatol. 1992;19:13–19.
   Web of Science ®Google Scholar
• Lister BJ, Poland M, Delapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med. 1993;95:3S–9S.
   Google Scholar
• Emery P, Clarke A, Williams P, et al. Nabumetone compared with naproxen in the treatment of rheumatoid arthritis: a multicenter, double blind, randomized, parallel group trial in hospital outpatients. J Rheumatol. 1992;19:41–47.
   Web of Science ®Google Scholar
• Pelletier JP, Martel-Pelletier J, Rannou F, et al. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45:S22–7.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Ganci A, Panara MR, et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 1995;58:335–341.
   PubMed Web of Science ®Google Scholar
• Ciabattoni G, Cinotti GA, Pierucci A, et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. N Engl J Med. 1984;310:279–283.
   PubMed Web of Science ®Google Scholar
• Brater DC, Anderson S, Baird B, et al. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 1985;27:66–73.
   PubMed Web of Science ®Google Scholar
• Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney In. 1987;32:1–12.
   PubMed Web of Science ®Google Scholar
• Kulling PE, Backman EA, Skagius AS, et al. Renal impairment after acute diclofenac, naproxen, and sulindac overdoses. J Toxicol Clin Toxicol. 1995;33:173–177.
   PubMed Web of Science ®Google Scholar
• Altman R, Bosch B, Brune K, et al. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs. 2015;75:859–877.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. for the VIGOR study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl J Med. 2000;343:1520–1528.
   PubMed Web of Science ®Google Scholar
• Henry D, Lim LL, García Rodríguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Bmj. 1996;312:1563–1566.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, et al. TARGET study group, comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet. 2004;364:665–674.
   PubMed Web of Science ®Google Scholar
• Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17–33.
   PubMed Web of Science ®Google Scholar
• da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016;387:2093–2105.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162:46–54.
   PubMed Web of Science ®Google Scholar
• Massó González EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62:1592–1601.
   PubMed Web of Science ®Google Scholar
• Schmassmann A, Zoidl G, Peskar BM, et al. Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and −2 knockout mice. Am J Physiol Gastrointest Liver Physiol. 2006;290:G747–G756.
   PubMed Web of Science ®Google Scholar
• Shigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther. 1998;286:1383–1390.
   PubMed Web of Science ®Google Scholar
• Mizuno H, Akamatsu T, Kasuga M. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997;112:387–397.
   PubMed Web of Science ®Google Scholar
• Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanism and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418–1423.
   PubMed Web of Science ®Google Scholar
• Bruno A, Tacconelli S, Patrignani P. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives. Basic Clin Pharmacol Toxicol. 2014;114:56–63.
   PubMed Web of Science ®Google Scholar
• Korotkova M, Jakobsson PJ. Characterization of microsomal prostaglandin E synthase 1 inhibitors. Basic Clin Pharmacol Toxicol. 2014;114:64–69.
   PubMed Web of Science ®Google Scholar
• Wang M, Ihida-Stansbury K, Kothapalli D, et al. Microsomal prostaglandinE2 synthase-1 modulates the response to vascular injury. Circulation. 2011;123:631–639.
   PubMed Web of Science ®Google Scholar